標(biāo)題: Titlebook: Drug Target miRNA; Methods and Protocol Marco F. Schmidt Book 2017 Springer Science+Business Media, LLC, part of Springer Nature 2017 drug [打印本頁(yè)] 作者: 根深蒂固 時(shí)間: 2025-3-21 19:40
書目名稱Drug Target miRNA影響因子(影響力)
作者: 文件夾 時(shí)間: 2025-3-21 22:52 作者: NOCT 時(shí)間: 2025-3-22 03:08 作者: Medicaid 時(shí)間: 2025-3-22 07:18 作者: Factorable 時(shí)間: 2025-3-22 10:17
Ausblick: Eine Roadmap der FAS 2003 – 2006olecules targeting miRNAs is a useful technology platform for anticancer drug development. Here, we describe a hepatocellular carcinoma (HCC) cell-based luciferase reporter system which could be used to screen for small molecule modulators of tumor suppressor microRNA-34a.作者: Custodian 時(shí)間: 2025-3-22 15:11
Competitive Argonaute-Based RNA Immunoprecipitation for Investigation of Transcriptomic Response to elopmental therapeutics that modulate miRNAs, such as anti-miRNA oligonucleotides (anti-miR). Here, we describe a method that uses changes in Argonaute 2-RNA immunoprecipitation in response to competition by anti-miR, titrated ex vivo, as physical evidence for target validation.作者: Custodian 時(shí)間: 2025-3-22 19:53 作者: 微不足道 時(shí)間: 2025-3-22 21:15 作者: 殺菌劑 時(shí)間: 2025-3-23 02:08 作者: 揉雜 時(shí)間: 2025-3-23 09:27 作者: 急急忙忙 時(shí)間: 2025-3-23 13:08
To Play by the Rules of the Gameical association of miRNA inhibitors and their targets in the context of the Argonaute complex in vivo, providing unprecedented insight into the physiological interactions of anti-miRs and the miRNA machinery.作者: Morose 時(shí)間: 2025-3-23 14:45
,Einwendungsm?glichkeiten des Zahnarztes,termine if a compound is able to impair the loading of miRNAs on AGO2 protein. Here, we describe these two methodologies that we recently used to select a specific compound able to interfere with the AGO2 functional activity and able to improve the retinoic acid-dependent myeloid differentiation of leukemic cells.作者: tackle 時(shí)間: 2025-3-23 19:20 作者: 嚴(yán)厲譴責(zé) 時(shí)間: 2025-3-24 02:00 作者: chapel 時(shí)間: 2025-3-24 03:00 作者: galley 時(shí)間: 2025-3-24 08:21 作者: jabber 時(shí)間: 2025-3-24 13:30
Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule Argonaute 2 Pr the film, monitored in real time as a change in the position of the dip in reflected intensity. Since SPR detects mass, the technique is label-free..Here, we describe the use of SPR techniques to study the interaction between Argonaute 2 and small molecular compounds selected by means of high-throughput docking screening.作者: osculate 時(shí)間: 2025-3-24 18:12 作者: 有幫助 時(shí)間: 2025-3-24 19:42
Antagonists of the miRNA-Argonaute 2 Protein Complex: Anti-miR-AGOsr lower molecular weight and, thus, more drug-like chemical structure, the novel inhibitor class may show better pharmacokinetic properties than reported oligonucleotide inhibitors, enabling them for potential therapeutic use.作者: cajole 時(shí)間: 2025-3-25 00:14 作者: 矛盾心理 時(shí)間: 2025-3-25 04:10 作者: Dysarthria 時(shí)間: 2025-3-25 10:40
Gespr?chskompetenz im I-can-EIB-System, thus guiding drug optimization for enhancing or avoiding these activities as desired. This chapter outlines the miRNA Polysome Shift Assay technique, describes sample preparation and quality control, and how to calculate and interpret results.作者: Venules 時(shí)間: 2025-3-25 14:17
Die Entwicklungsgeschichte von I-can-EIBor creation of predictive models from high-throughput biological screens for virtual screening of small molecules with the potential to inhibit microRNAs. Such models could be potentially used for computational prioritization of small molecules before performing high-throughput biological assay.作者: aneurysm 時(shí)間: 2025-3-25 17:26 作者: expeditious 時(shí)間: 2025-3-25 23:44 作者: saphenous-vein 時(shí)間: 2025-3-26 01:54 作者: companion 時(shí)間: 2025-3-26 05:12 作者: 戰(zhàn)勝 時(shí)間: 2025-3-26 11:12 作者: indecipherable 時(shí)間: 2025-3-26 13:21
1064-3745 thods and Protocols. is a valuable resource for anyone interested in the ever-evolving field of miRNA drug discovery...?.978-1-4939-8236-3978-1-4939-6563-2Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 槍支 時(shí)間: 2025-3-26 17:27 作者: 參考書目 時(shí)間: 2025-3-26 21:17
Non-nucleotide Modification of Anti-miRNA Oligonucleotides This protocol describes use of ZEN AMOs in a dual-luciferase reporter assay as a simplified means to validate AMO performance or to quickly test putative miRNA binding sites in target sequences. This protocol also describes a method using Western blot analysis for quantifying the level of upregulat作者: FUME 時(shí)間: 2025-3-27 03:26
Rapid Generation of miRNA Inhibitor Leads by Bioinformatics and Efficient High-Throughput Screening ting adaptation of breast cancer cells to hypoxic stress. Herein, we describe a protocol that utilizes bioinformatics to first identify lead small molecules that bind to DICER cleavage sites in pre-miRNAs and then employ an efficient, high-throughput fluorescent-based screening system to determine t作者: circuit 時(shí)間: 2025-3-27 09:21 作者: 陳舊 時(shí)間: 2025-3-27 11:25 作者: Mundane 時(shí)間: 2025-3-27 14:57
Confidence: The “Flywheel” Turns This protocol describes use of ZEN AMOs in a dual-luciferase reporter assay as a simplified means to validate AMO performance or to quickly test putative miRNA binding sites in target sequences. This protocol also describes a method using Western blot analysis for quantifying the level of upregulat作者: 頌揚(yáng)國(guó)家 時(shí)間: 2025-3-27 18:54
,Ausgew?hlte Konstruktionstheorieen,ting adaptation of breast cancer cells to hypoxic stress. Herein, we describe a protocol that utilizes bioinformatics to first identify lead small molecules that bind to DICER cleavage sites in pre-miRNAs and then employ an efficient, high-throughput fluorescent-based screening system to determine t作者: ovation 時(shí)間: 2025-3-27 23:49 作者: 相信 時(shí)間: 2025-3-28 03:09
Functional Analysis of miRNAs Using the DIANA Tools Online Suiteal conditions but also as diagnostic biomarkers or promising therapeutic targets. The increased complexity of the miRNA interactomes hinders straightforward interpretation of miRNA expression differences between states and conditions. To this end, functional analysis web servers process and combine 作者: tattle 時(shí)間: 2025-3-28 09:02
Non-nucleotide Modification of Anti-miRNA Oligonucleotidescking antisense oligonucleotides (ASOs) that inhibit miRNA function through high-affinity binding and subsequent inactivation and/or degradation of the targeted miRNA. AMOs are a primary tool used to empirically determine the biological targets of a miRNA and can also be used therapeutically when ov作者: 慟哭 時(shí)間: 2025-3-28 13:30 作者: 蜿蜒而流 時(shí)間: 2025-3-28 16:32 作者: acheon 時(shí)間: 2025-3-28 21:13
Competitive Argonaute-Based RNA Immunoprecipitation for Investigation of Transcriptomic Response to have in healthy and diseased cells. From a practical standpoint, validated target genes are also useful for monitoring pharmacological activity of developmental therapeutics that modulate miRNAs, such as anti-miRNA oligonucleotides (anti-miR). Here, we describe a method that uses changes in Argonaut作者: 占卜者 時(shí)間: 2025-3-29 00:44
Assessing Anti-miR Pharmacology with miRNA Polysome Shift Assay Shift Assay enables measurement of anti-miR drug target engagement (i.e. extent of miRNA inhibition) without the need to pre-identify or pre-validate downstream miRNA-regulated genes. This makes it useful for assessing anti-miR activity in target tissues or cells where biology of the inhibited miRN作者: 憤怒歷史 時(shí)間: 2025-3-29 03:57
Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Culle oncogenic pathways and, therefore, provide a strong rationale for developing therapeutic miRNA mimics in combination with other therapeutic cancer agents to augment drug sensitivity. Here, we describe the experimental approach for evaluating miRNA and drug combinations using the “fixed ratio” met作者: 錯(cuò)事 時(shí)間: 2025-3-29 10:20
Assessing the Off-Target Effects of miRNA Inhibitors on Innate Immune Toll-Like Receptorspresent novel therapeutic opportunities. Currently, in vivo delivery of AMOs often relies on high doses of nucleic acids, with nonspecific uptake by most tissues. Critically, AMOs accumulate in phagocytic cells where they can interfere with immune functions, such as the activation of Toll-Like Recep作者: prostatitis 時(shí)間: 2025-3-29 15:02
Design of Multimodal Small Molecules Targeting miRNAs Biogenesis: Synthesis and In Vitro Evaluationtext, the discovery of small-molecule drugs targeting specific miRNAs and modulating their production or function represents a very promising approach that could be further developed for targeted therapy in miRNA-related pathologies. Here, we describe the design of multimodal small molecules as RNA 作者: 容易懂得 時(shí)間: 2025-3-29 19:22
Machine Learning Approaches Toward Building Predictive Models for Small Molecule Modulators of miRNAng small molecules offer an attractive means for modulating miRNA function. The availability of bioassay data sets for a variety of biological assays and molecules in public domain provides a new opportunity toward utilizing them to create models and further utilize them for in silico virtual screen作者: Brocas-Area 時(shí)間: 2025-3-29 22:14
Identification of Small Molecule Modulators of MicroRNA by Library Screening for cancer. Small molecules that could modulate the expression of miRNAs would thus have potential as anticancer agents. Library screening of small molecules targeting miRNAs is a useful technology platform for anticancer drug development. Here, we describe a hepatocellular carcinoma (HCC) cell-bas作者: atopic 時(shí)間: 2025-3-30 03:17 作者: Ledger 時(shí)間: 2025-3-30 04:25 作者: 厚顏 時(shí)間: 2025-3-30 08:58
Small Molecules Targeting the miRNA-Binding Domain of Argonaute 2: From Computer-Aided Molecular Des (miRNA) mimicking compounds able to bind the miRNA-binding domain of Argonaute 2 protein (AGO2) to inhibit miRNA loading and its functional activity were described. Computer-aided molecular design techniques and RNA immunoprecipitation represent suitable approaches to identify and experimentally de作者: 山羊 時(shí)間: 2025-3-30 13:03 作者: 治愈 時(shí)間: 2025-3-30 18:25 作者: Condescending 時(shí)間: 2025-3-30 23:38
Drug Target miRNA978-1-4939-6563-2Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: circumvent 時(shí)間: 2025-3-31 04:22
Jan Feindt,Claudia Jan?en,Stefan S?lbrandtle oncogenic pathways and, therefore, provide a strong rationale for developing therapeutic miRNA mimics in combination with other therapeutic cancer agents to augment drug sensitivity. Here, we describe the experimental approach for evaluating miRNA and drug combinations using the “fixed ratio” method in cultured non-small cell lung cancer cells.作者: CHOIR 時(shí)間: 2025-3-31 08:45 作者: 學(xué)術(shù)討論會(huì) 時(shí)間: 2025-3-31 12:18 作者: RAFF 時(shí)間: 2025-3-31 16:10
Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Culle oncogenic pathways and, therefore, provide a strong rationale for developing therapeutic miRNA mimics in combination with other therapeutic cancer agents to augment drug sensitivity. Here, we describe the experimental approach for evaluating miRNA and drug combinations using the “fixed ratio” method in cultured non-small cell lung cancer cells.
